RA CAPITAL MANAGEMENT, L.P.
SEC CIK 1346824 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| SION | Sionna Therapeutics, Inc. | Dir, 10% | 3.45M | $20.25M | $27.34M | 4 | 2025-02-10 | 2026-09-17 |
| VOR | Vor Biopharma Inc. | Dir, 10% | 1,500 | — | $55.62M | 10 | 2025-10-23 | 2026-08-24 |
| SEPN | Septerna, Inc. | Dir, 10% | 725.4K | — | $63.45M | 1 | 2026-08-12 | 2026-08-12 |
| ARTV | Artiva Biotherapeutics, Inc. | Dir, 10% | 17.33M | $92.68M | — | 10 | 2026-05-11 | 2026-07-29 |
| IKT | Inhibikase Therapeutics, Inc. | 10% | 6.97M | — | — | 1 | 2026-07-29 | 2026-07-29 |
| FRNM | Freenome, Inc. | Dir, 10% | 1.25M | — | — | 1 | 2026-07-20 | 2026-07-20 |
| PBLS | Parabilis Medicines, Inc. | Dir, 10% | 26.53M | $430.69M | — | 3 | 2026-06-11 | 2026-07-20 |
| HOWL | Werewolf Therapeutics, Inc. | 10% | 303.7K | — | $963.9K | 4 | 2026-05-08 | 2026-06-17 |
| COAG | Hemab Therapeutics Holdings, Inc. | Dir, 10% | 6.44M | $55.46M | — | 6 | 2026-05-04 | 2026-06-15 |
| JANX | Janux Therapeutics, Inc. | Dir, 10% | 11.8K | — | — | 2 | 2024-06-26 | 2026-06-11 |
| ABOS | Acumen Pharmaceuticals, Inc. | Dir, 10% | 48.3K | $40.00M | — | 2 | 2023-07-21 | 2026-06-03 |
| ACRV | Acrivon Therapeutics, Inc. | Dir, 10% | 9,366 | — | — | 2 | 2026-04-22 | 2026-05-18 |
| ACET | Adicet Bio, Inc. | 10% | 932.6K | $1.60M | — | 2 | 2026-02-18 | 2026-04-27 |
| PRLD | Prelude Therapeutics Inc | 10% | 6.48M | — | — | 1 | 2026-04-27 | 2026-04-27 |
| WVE | Wave Life Sciences, Inc. | Dir, 10% | 23.16M | $59.63M | — | 4 | 2023-12-11 | 2026-03-26 |
| BCAX | Bicara Therapeutics Inc. | Dir, 10% | 4.60M | $4.80M | — | 1 | 2026-02-26 | 2026-02-26 |
| EVMN | Evommune, Inc. | Dir, 10% | 691.4K | $20.00M | — | 2 | 2025-11-07 | 2025-11-07 |
| MLYS | Mineralys Therapeutics, Inc. | Dir | 5.46M | $30.00M | — | 2 | 2024-02-12 | 2025-09-04 |
| TYRA | Tyra Biosciences, Inc. | Dir, 10% | 10.25M | $1.66M | — | 1 | 2025-06-12 | 2025-06-12 |
| FDMT | 4D Molecular Therapeutics, Inc. | 10% | 4.56M | — | — | 1 | 2024-12-09 | 2024-12-09 |
| NKTX | Nkarta, Inc. | Dir, 10% | 10.05M | $30.00M | — | 1 | 2024-03-27 | 2024-03-27 |
| SPRY | ARS Pharmaceuticals, Inc. | Dir, 10% | 8.99M | $36.54M | — | 2 | 2023-08-29 | 2024-03-25 |
| BDTX | Black Diamond Therapeutics, Inc. | Dir | 3.21M | $4.68M | — | 1 | 2023-07-05 | 2023-07-05 |
| FULC | Fulcrum Therapeutics, Inc. | 10% | 11.61M | $38.08M | — | 2 | 2022-12-14 | 2023-01-20 |
| ELVN | Enliven Therapeutics, Inc. | 10% | 3.88M | $2.52M | — | 1 | 2023-01-03 | 2023-01-03 |
| SLDB | Solid Biosciences Inc. | Dir, 10% | 2.99M | — | — | 1 | 2022-12-02 | 2022-12-02 |
| CTKB | Cytek Biosciences, Inc. | Dir | 9.94M | $7.43M | — | 1 | 2022-02-14 | 2022-02-14 |
Most active insiders at SION, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Thompson Peter A. | Dir | — | $55.67M |
| 2 | ORBIMED ADVISORS LLC | Dir | — | $52.73M |
| 3 | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | — | $27.34M |
| 4 | Booth Bruce | Dir | — | $22.09M |
| 5 | RA Capital Nexus Fund III, L.P. | Dir | — | $14.76M |
| 6 | WINKELRIED JON | 10% | — | $10.00M |
| 7 | Cloonan Michael | Pres, CEO, Dir | — | $5.13M |
| 8 | OrbiMed Capital GP VIII LLC | Dir | — | $2.95M |
| 9 | Fitzpatrick Jennifer | CLO, Head of Program Mgmt | — | $1.21M |
| 10 | Kolchinsky Peter | Dir, 10% | — | $1.20M |
Transactions 69
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2026-09-21 18:56 | 2026-09-17 | SION | Sionna Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | S - Sale | $6.33 | -3.45M | 3.45M | -50% | -$21.84M |
| DI | 2026-08-26 18:28 | 2026-08-24 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% | M - OptEx | $3.74 | +1,500 | 1,500 | New | +$5,604 |
| MI | 2026-08-14 17:11 | 2026-08-12 | SEPN | Septerna, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | S - Sale | $42.50 | -1.49M | 725.4K | -67% | -$63.45M |
| MI | 2026-07-31 17:13 | 2026-07-29+ | ARTV | Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $9.96 | +45.8K | 17.33M | +0.3% | +$455.7K |
| DI | 2026-07-31 16:32 | 2026-07-29 | IKT | Inhibikase Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% | J - Other | — | -18.03M | 6.97M | -72% | — |
| I | 2026-07-28 17:24 | 2026-07-24 | ARTV | Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $9.99 | +41.3K | 17.28M | +0.2% | +$412.8K |
| MI | 2026-07-23 21:22 | 2026-07-21+ | ARTV | Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $9.76 | +264.6K | 17.24M | +2% | +$2.58M |
| AI | 2026-07-23 21:21 | 2026-07-13 | ARTV | Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $8.94 | +6,522 | 16.82M | +0.0% | +$58.3K |
| MI | 2026-07-22 17:31 | 2026-07-20 | FRNM | Freenome, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | A - Grant | $10.00 | +14.62M | 1.25M | New | +$146.17M |
| MI | 2026-07-22 16:55 | 2026-07-20+ | PBLS | Parabilis Medicines, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $28.29 | +244.6K | 26.53M | +0.9% | +$6.92M |
| DI | 2026-07-21 16:54 | 2026-07-16 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% | X - OptEx | $0.002 | +2.10M | 4.50M | +87% | +$4,200 |
| DI | 2026-07-21 16:54 | 2026-07-16 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% | S - Sale+OE | $19.75 | -213 | 4.50M | -0.0% | -$4,207 |
| MI | 2026-07-20 18:08 | 2026-07-16+ | ARTV | Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $8.93 | +160.4K | 16.98M | +1.0% | +$1.43M |
| MI | 2026-07-14 19:00 | 2026-07-10+ | ARTV | Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $8.96 | +21.7K | 16.82M | +0.1% | +$194.0K |
| MI | 2026-06-29 16:20 | 2026-06-25+ | ARTV | Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $8.89 | +32.9K | 16.80M | +0.2% | +$292.1K |
| MI | 2026-06-22 18:59 | 2026-06-17 | HOWL | Werewolf Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% | S - Sale | $0.35 | -416.9K | 303.7K | -58% | -$145.9K |
| MI | 2026-06-17 18:24 | 2026-06-15+ | COAG | Hemab Therapeutics Holdings, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% | P - Purchase | $24.97 | +67.7K | 6.44M | +1% | +$1.69M |
| MI | 2026-06-16 18:08 | 2026-06-12+ | ARTV | Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $8.66 | +531.3K | 16.76M | +3% | +$4.60M |
| MI | 2026-06-16 18:01 | 2026-06-12+ | HOWL | Werewolf Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% | S - Sale | $0.3871 | -448.8K | 331.4K | -58% | -$173.8K |
| DMI | 2026-06-15 18:57 | 2026-06-11 | PBLS | Parabilis Medicines, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | C - Cnv Deriv | — | +7.74M | 1.19M | New | — |
| DMI | 2026-06-15 18:57 | 2026-06-11 | PBLS | Parabilis Medicines, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $20.00 | +21.19M | 2.65M | New | +$423.77M |
| DI | 2026-06-12 20:30 | 2026-06-11 | JANX | Janux Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | A - Grant | $0.00 | +5,500 | 11.8K | +88% | $0 |
| MI | 2026-06-11 20:13 | 2026-06-09+ | HOWL | Werewolf Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% | S - Sale | $0.3739 | -678.2K | 361.2K | -65% | -$253.6K |
| MI | 2026-06-11 19:36 | 2026-06-09+ | ARTV | Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $7.44 | +1.03M | 16.23M | +7% | +$7.65M |
| DI | 2026-06-05 17:12 | 2026-06-03 | ABOS | Acumen Pharmaceuticals, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | A - Grant | $0.00 | +35.5K | 48.3K | +277% | $0 |
| MI | 2026-05-21 16:20 | 2026-05-19+ | COAG | Hemab Therapeutics Holdings, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% | P - Purchase | $24.96 | +4,798 | 6.38M | +0.1% | +$119.8K |
| I | 2026-05-20 16:59 | 2026-05-18 | ACRV | Acrivon Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | A - Grant | $0.00 | +9,366 | 9,366 | New | $0 |
| I | 2026-05-14 17:21 | 2026-05-12 | COAG | Hemab Therapeutics Holdings, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% | P - Purchase | $24.90 | +6,387 | 6.37M | +0.1% | +$159.0K |
| DI | 2026-05-13 17:45 | 2026-05-11 | ARTV | Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $11.52 | +6.51M | 15.20M | +75% | +$75.00M |
| MI | 2026-05-12 18:26 | 2026-05-08+ | HOWL | Werewolf Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% | S - Sale | $0.6913 | -565.2K | 406.3K | -58% | -$390.7K |
| MI | 2026-05-11 17:44 | 2026-05-07+ | COAG | Hemab Therapeutics Holdings, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% | P - Purchase | $24.75 | +51.3K | 6.37M | +0.8% | +$1.27M |
| DMI | 2026-05-06 19:16 | 2026-05-04 | COAG | Hemab Therapeutics Holdings, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | C - Cnv Deriv | — | +4.84M | 221.2K | New | — |
| DMI | 2026-05-06 19:16 | 2026-05-04+ | COAG | Hemab Therapeutics Holdings, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $18.39 | +2.84M | 6.31M | +82% | +$52.22M |
| DI | 2026-04-29 16:15 | 2026-04-27 | ACET | Adicet Bio, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% | J - Other | — | -250.0K | 932.6K | -21% | — |
| DI | 2026-04-28 17:14 | 2026-04-27 | PRLD | Prelude Therapeutics Inc | RA CAPITAL MANAGEMENT, L.P. | 10% | J - Other | — | -1.41M | 6.48M | -18% | — |
| I | 2026-04-24 18:12 | 2026-04-22 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | S - Sale | $15.77 | -165.2K | 2.40M | -6% | -$2.60M |
| I | 2026-04-23 16:28 | 2026-04-22 | ACRV | Acrivon Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | A - Grant | $1.80 | +3.89M | 11.80M | +49% | +$7.00M |
| MI | 2026-04-21 19:04 | 2026-04-17+ | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | S - Sale | $16.14 | -630.4K | 2.57M | -20% | -$10.17M |
| MI | 2026-04-15 17:29 | 2026-04-13+ | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | S - Sale | $16.10 | -738.0K | 3.20M | -19% | -$11.88M |
| MI | 2026-04-13 17:20 | 2026-02-18+ | ACET | Adicet Bio, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% | P - Purchase | $7.17 | +223.6K | 1.18M | +23% | +$1.60M |
| MI | 2026-04-10 18:23 | 2026-04-08+ | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | S - Sale | $16.50 | -620.1K | 3.94M | -14% | -$10.23M |
| MI | 2026-04-06 18:51 | 2026-04-02+ | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | S - Sale | $17.10 | -849.3K | 4.56M | -16% | -$14.52M |
| MI | 2026-03-30 | 2026-03-26+ | WVE | Wave Life Sciences, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $6.23 | +8.77M | 23.16M | +61% | +$54.62M |
| DI | 2026-03-02 | 2026-02-26 | BCAX | Bicara Therapeutics Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $16.00 | +300.0K | 4.60M | +7% | +$4.80M |
| DI | 2025-12-19 | 2025-12-18 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | A - Grant | $10.81 | -4.63M | 5.40M | -46% | -$50.00M |
| MI | 2025-11-19 | 2025-11-17+ | SION | Sionna Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | S - Sale | $40.34 | -136.4K | 182.5K | -43% | -$5.50M |
| I | 2025-11-14 | 2025-11-13 | WVE | Wave Life Sciences, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $6.69 | +1,000 | 18.20M | +0.0% | +$6,690 |
| DMI | 2025-11-12 | 2025-11-07 | EVMN | Evommune, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | C - Cnv Deriv | — | +2.21M | 691.4K | New | — |
| DMI | 2025-11-12 | 2025-11-07 | EVMN | Evommune, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $16.00 | +1.25M | 784.3K | New | +$20.00M |
| MI | 2025-10-27 | 2025-10-23+ | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | S - Sale | $28.06 | -221.2K | 1.27M | -15% | -$6.20M |
| I | 2025-09-08 | 2025-09-04 | MLYS | Mineralys Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir | P - Purchase | $25.50 | +1.18M | 5.46M | +27% | +$30.00M |
| MI | 2025-06-16 | 2025-06-12+ | TYRA | Tyra Biosciences, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $10.19 | +163.3K | 10.25M | +2% | +$1.66M |
| DMI | 2025-02-10 | 2025-02-10 | SION | Sionna Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | C - Cnv Deriv | — | +7.95M | 327.8K | New | — |
| DMI | 2025-02-10 | 2025-02-10 | SION | Sionna Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $18.00 | +1.12M | 2.32M | +94% | +$20.25M |
| DI | 2024-12-10 | 2024-12-09 | FDMT | 4D Molecular Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% | J - Other | $0.00 | -535.0K | 4.56M | -10% | $0 |
| DI | 2024-08-14 | 2024-08-12 | WVE | Wave Life Sciences, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | A - Grant | $0.00 | +16.1K | 16.1K | New | $0 |
| DI | 2024-06-28 | 2024-06-26 | JANX | Janux Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | A - Grant | $0.00 | +2,500 | 2,500 | New | $0 |
| DI | 2024-03-29 | 2024-03-27 | NKTX | Nkarta, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $10.00 | +3.00M | 10.05M | +43% | +$30.00M |
| MI | 2024-03-27 | 2024-03-25+ | SPRY | ARS Pharmaceuticals, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $9.48 | +1.40M | 8.99M | +18% | +$13.29M |
| DI | 2024-02-14 | 2024-02-12 | MLYS | Mineralys Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir | A - Grant | $13.50 | +1.67M | 2.98M | +128% | +$22.58M |
| AI | 2024-01-17 | 2023-12-11 | WVE | Wave Life Sciences, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $5.00 | +1.00M | 18.20M | +6% | +$5.00M |
| I | 2023-08-31 | 2023-08-29 | SPRY | ARS Pharmaceuticals, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir | P - Purchase | $6.20 | +3.75M | 5.86M | +178% | +$23.25M |
| I | 2023-07-25 | 2023-07-21 | ABOS | Acumen Pharmaceuticals, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | P - Purchase | $7.75 | +5.16M | 13.04M | +65% | +$40.00M |
| I | 2023-07-07 | 2023-07-05 | BDTX | Black Diamond Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir | P - Purchase | $5.00 | +935.9K | 3.21M | +41% | +$4.68M |
| I | 2023-01-24 | 2023-01-20 | FULC | Fulcrum Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% | P - Purchase | $13.00 | +1.92M | 11.61M | +20% | +$25.00M |
| I | 2023-01-05 | 2023-01-03 | ELVN | Enliven Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% | P - Purchase | $4.00 | +629.3K | 3.88M | +19% | +$2.52M |
| MI | 2022-12-16 | 2022-12-14+ | FULC | Fulcrum Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% | P - Purchase | $5.44 | +2.40M | 8.06M | +42% | +$13.08M |
| MI | 2022-12-05 | 2022-12-02 | SLDB | Solid Biosciences Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | A - Grant | $7.05 | +2.57M | 2.99M | +621% | +$18.14M |
| MI | 2022-02-16 | 2022-02-14+ | CTKB | Cytek Biosciences, Inc. | RA CAPITAL MANAGEMENT, L.P. | Dir | P - Purchase | $14.90 | +498.6K | 9.94M | +5% | +$7.43M |
Purchase Sale Sale after option exercise All abbreviations